Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Piramal Pharma Ltd.
Swot
Piramal Pharma Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Piramal Pharma Ltd. has 18 Strengths, 11 Weaknesses, 7 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(18)
Weakness
(11)
Opportunity
(7)
Threats
(1)
Others
(2)
MACD Crossover Above Signal Line
Stocks in Buy Zone with High Momentum Score Last Month
Relative Outperformance versus Industry over 1 Year
Companies with high TTM EPS Growth
Growth Stars: Strongest Annual EPS Performers
Expensive Performers (DVM)
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Companies with rising net profit margins - quarterly as well as TTM basis
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Net Profit with increasing Profit Margin (QoQ)
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
MACD crossed above signal line previous end of day
Negative Breakdown First Support (LTP < S1)
PE higher than Industry PE
High PE (PE > 40)
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Declining Net Cash Flow : Companies not able to generate net cash
Weak Momentum: Price below Short, Medium and Long Term Averages
Increasing Trend in Non-Core Income
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter
Mutual Funds Increased Shareholding in Past Month
Street Favorite: High Analyst Rating with at least 20% upside
Highest FII stock holdings
FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months
Broker downgrades in price or recommendation in the past one month
Bullish or Bearish Candlestick Strength - Indices
Expensive Performers (DVM)
